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Abstract
Observational studies of health conditions and outcomes often combine clinical care data from many sites without explicitly
assessing the accuracy and completeness of these data. In order to improve the quality of data in an international multi-site
observational cohortof HIV-infectedpatients,theauthorsconductedon-site,GoodClinicalPractice-based auditsof the clinical
care datasets submitted byparticipating HIVclinics.Discrepanciesbetween data submittedforresearch anddata inthe clinical
records were categorized using the audit codes published by the European Organization for the Research and Treatment of
Cancer. Five of seven sites had error rates .10% in key study variables, notably laboratory data, weight measurements, and
antiretroviral medications. All sites had significant discrepancies in medication start and stop dates. Clinical care data,
particularly antiretroviral regimens and associated dates, are prone to substantial error. Verifying data against source
documents through audits will improve the quality of databases and research and can be a technique for retraining staff
responsible for clinical data collection. Theauthors recommend that all participantsin observational cohorts usedata audits to
assess and improve the quality of data and to guide future data collection and abstraction efforts at the point of care.
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Introduction
Accurate and valid HIV research results depend on high-quality
clinical and laboratory data. Excellent patient care itself depends
on accurate recording and transcription of such information [1].
Interventional clinical trials, such as those generating data for pre-
marketing approval by regulatory agencies or those conducted by
the AIDS Clinical Trials Group [2], follow careful data quality
assurance procedures. This ensures that investigators comply with
the International Conference on Harmonization’s guidelines for
Good Clinical Practice and that collected data reflect true
measurements [3,4]. A data audit, in which an external review
team compares a research dataset to the original data collection
documents, is the standard method of assessing the quality of data
in clinical trials [5–8].
Depending on the nature of the research question, researchers
and funding agencies may use routine patient care data as a
readily available and inexpensive supplement or alternative to data
generated through prospective clinical trials [9,10]. Databases that
pool such observational data from multiple, international sites
have become particularly important resources for HIV/AIDS
research due to increased interest in measuring global trends in the
epidemic and the side effects and long-term outcomes of
antiretroviral (ARV) therapy [11–15]. Routine medical care data,
however, do not undergo the same stringent quality controls
commonly applied in clinical trials. International multi-center
HIV networks that use routine patient care data may be at higher
risk of having data quality issues because monitoring for quality at
geographically distant locations is difficult, time-consuming, and
expensive.
Many networks that repurpose routine medical care data for
research rely on data cleaning and cross-referencing performed at
the data coordinating center [16]. These techniques can confirm
the data’s internal consistency and identify missing values but
cannot determine data accuracy and authenticity. Comparing
research data to their source documents through audits is therefore
an essential additional step in verifying the data’s accuracy [17].
Despite the importance of using high-quality data, no multi-center
observational HIV cohort has published research indicating that
they conducted frequent source-to-database data audits. As a
result, the quality of data and the accuracy of results from many
multi-site HIV cohorts can be uncertain.
We evaluated the accuracy and completeness, as assessed by on-
site data audits, of routine patient care data submitted for research
by seven sites participating in an international collaborative HIV
research network: the Caribbean, Central and South America
Network for HIV Epidemiology (CCASAnet).
Methods
Network description
CCASAnet is one of seven regional networks that belong to
International Epidemiologic Databases to Evaluate AIDS (Ie-
DEA), an international, multi-center research consortium funded
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e33908by the U.S. National Institutes of Health [13]. The CCASAnet
project aims to create a shared repository of HIV data from
participating clinics and hospitals in Latin America and the
Caribbean, to use the combined data to examine regional HIV
epidemic characteristics, and to contribute to worldwide IeDEA
studies [18,19]. Seven urban HIV/AIDS treatment centers
participate in the network, including sites in Argentina, Brazil,
Chile, Haiti, Honduras, Mexico, and Peru, and the network is
overseen by a data coordinating center (DCC) at Vanderbilt
University in Nashville, Tennessee, USA. To preserve the
anonymity of the clinics, we have labeled them randomly as sites
A–G.
All seven CCASAnet sites used paper medical records as the
primary means of storing patient information. The paper clinical
records generally contained a structured patient intake form and
handwritten follow-up visit notes. Nursing staff at sites D, F, and G
maintained detailed drug dispensing forms that were kept with the
patient chart and used to verify drug prescriptions and dates. The
different data collection practices and resources at each audit site
are detailed in Table 1.
At all sites, a team of clinicians, data entry personnel, or
administrative staff abstracted information from the paper medical
record and entered the results into an electronic research database
from which data were extracted for CCASAnet studies. Sites B, C,
and F had access to electronic laboratory systems that exported
test results directly into their research databases. The majority of
these databases were designed and maintained by local staff and
implemented in Microsoft Access. One site used a commercial
data warehousing service in place of an on-site database server.
Two of the seven sites employed experienced data managers (B,
C); three of the remaining sites had data managers without formal
training (A, D, G.) Only Site C operated an extensive data center.
Site F was the only site that actively conducted internal quality
reviews of their research data.
The Vanderbilt University Medical Center Institutional Review
Board approved this project. Local centers de-identified all data
before transmitting it to the DCC, so no informed consent was
required.
Data audit preparation and process
Between April 2007 and March 2008, a team from the DCC –
including at least one HIV clinician and one informaticist –
conducted on-location audits of the datasets received from
CCASAnet member sites. Our audit techniques involved verifying
data integrity using source documents and were adapted from
those used in clinical trials to ensure Good Clinical Practice (GCP)
compliance [3].
The DCC data manager selected approximately 30 records
from each site’s database using simple random sampling, so that
within a site’s dataset, each record had an equal probability of
being selected. We sent research identification numbers (IDs) for
the first 20 randomly selected records to the site ten days before
the data monitoring visit to allow local data personnel to retrieve
the records in advance. We requested the remaining ten records
from the site investigators on the first audit day.
Our initial audits lasted two to three days per site. Sites for
which we recommended major quality interventions were re-
audited during the current or subsequent audit cycle. During each
audit, we compared the contents of the study database to the local
source documents and noted discrepancies and inconsistencies in
individual data elements. The available source documents
included paper clinical records and, where available, electronic
laboratory, pharmacy, and medical record reports. We reviewed
as many source documents as the sites could locate during the visit
and consulted local site personnel for clarifications as needed.
Audit findings were recorded on a structured paper audit form and
later entered into an Excel spreadsheet for analysis.
The audited variables included those most relevant to proposed
consortium studies: patient demographics, HIV-related risk
factors, weight measurements, CD4
+ lymphocyte (CD4) counts,
plasma HIV-1 RNA levels (viral load), all ARV regimens, and all
dates associated with each measurement. When a patient’s ARV
regimen was recorded as ‘‘current’’ or ‘‘ongoing’’ in the database,
we verified that the patient was still taking the specified drug
combination around the time the site data were submitted to the
DCC.
Error classification
After each audit, we reviewed the completed paper audit forms
and categorized audit results using standardized audit codes from
the European Organization for the Research and Treatment of
Cancer (EORTC) [6]. The audit data were labeled correct (code
1) if the database values submitted to the DCC matched the values
in the paper clinical record or other on-site source documents.
Major errors (code 3) represented discrepancies between the
clinical record and database values that the physician on the audit
team deemed clinically meaningful. Other discrepancies were
labeled minor errors (code 2, e.g., weight values rounded to the
nearest integer, dates in the database within six days of the
documented date). Missing/missed data (code 4) included values
for requested information (e.g., baseline weight) that had been left
Table 1. Characteristics of data collection, abstraction, and management at audit sites A–G.
Sites
Characteristic A B C D E F G
Structured patient follow-up visit form Yes no no no no no no
Drug dispensing form no no no Yes no Yes Yes
Electronic laboratory system no Yes Yes no no Yes no
On-site research database (vs. commercially
hosted and managed database)
Yes Yes Yes Yes no Yes Yes
Data manager Yes Yes Yes Yes no no Yes
Full-time data abstraction team no no no Yes no no Yes
Internal data audits no no no no no Yes no
doi:10.1371/journal.pone.0033908.t001
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database but not in the clinical record were labeled sourceless
(code 5). One auditor performed the initial classification, a second
auditor reviewed all classifications, and all disagreements were
resolved by joint record review. A coded sample record is
presented in Table S1.
Statistical analysis
We calculated error rates by dividing the number of erroneous
clinical record/database value pairs (codes 3, 4, and 5) by the
number of audited value pairs. We compared error rates across
variables using a generalized linear mixed model to account for
correlations between variables from the same record and within
the same clinic. Analyses comparing major error rates (code 3)
between variables did not include missing or sourceless errors
(codes 4 and 5) in the denominator.
Results
We requested a total of 208 randomly selected patient records
during seven data audits at Sites A–G. Of these 208 records, 16
could not be located or were unavailable because they were
needed for patient care. The majority of missing records (11 of 16)
were from Site A. We reviewed 184 of the remaining 192 charts
(eight charts were not audited because of time constraints)
comprising 4,223 unique data points. The number of unavailable,
available, and audited charts by site is shown in Table 2.
The dataset of all audit results contained 3,581 correct data
points, 66 minor errors, 171 major errors, 274 missing values, and
131 sourceless values. Minor errors – which were not counted
towards error rates – included dates that were shifted by a few days
(45%), inappropriately rounded weight measurements (36%), and
weight, CD4, and viral load values where a probable typograph-
ical slip resulted in small and clinically insignificant value
differences (19%). All audited instances of patient gender were
correct, and all birth dates were correct at four of seven sites. At
the remaining three sites, 7–19% of the birth dates recorded in the
site database differed by a week or more from values in the clinical
record. Weight values and their associated dates were entered in
the database with few or no errors at Sites F and G. Error rates at
the remaining sites ranged from 11–93% for weight measurements
and 15–100% for weight dates. At the three sites with the highest
error rates, weight data missing from the database were the
primary cause of error (24–89% missing weight measurements and
24–100% missing weight dates).
Sites varied less in error rates for laboratory values: CD4 count
(1–21%), CD4 dates (1–27%), viral load (1–42%), and viral load
dates (0–42%). For the records with major errors, the median and
interquartile range (IQR) for absolute differences between the
database and chart values were 20 cells/mm
3 (9–101 cells/mm
3)
for CD4 count, 23 days (10–56 days) for CD4 date, 65,200 copies/
ml (47,000–145,600 copies/ml) for viral load, and 22 days (11.5–
50 days) for viral load dates. Table 3 shows the number of
variables audited at each site and their specific error rates.
Errors in antiretroviral data according to audit site and error
type (and their 95% confidence intervals) are shown in Figure 1
(regimen data) and Figure 2 (dates). For 7–26% of ARV regimens,
the drug combinations were missing from the site’s submitted
database, incorrectly entered into the database, or not substanti-
ated by content in the clinical record. Error rates for regimen start
and stop dates ranged from 10–56%. There was no difference in
error rates when comparing stopping and starting dates (P.0.25
for both major errors alone and overall errors.) For records with
major errors, the median absolute difference between start/stop
dates found in the chart and those recorded in the database was 88
days (IQR: 31–365 days).
Overall, the error rates for ARV regimen start and stop dates
were higher than the error rates for all other non-ARV dates,
including the dates of weight, CD4 count, and viral load
measurements (P,0.001 for all.) For CD4 count, viral load, and
ARV data, the associated dates had a higher rate of major errors
(category 3) than the actual values (P,0.001 for all sites), whereas
weight values had more major errors than weight dates (P=0.028
for all sites).
After the findings of the initial audit, Site B cleaned and
reabstracted their study data and quickly submitted an updated
version, allowing us to reaudit the site at the end of the initial audit
cycle. We reviewed 26 randomly selected records with 463
variables during this second audit at Site B; four additional records
we requested were not available during the audit period. We
observed reduced error rates in all variable categories. The overall
error rate dropped from 34% to 17% (Table 4).
Discussion
Our data audits revealed substantial error rates in data
submitted by all seven participating clinics. The majority of errors
were due to measurements found in clinical records that were not
entered into the database, laboratory values with no source
documents, and incorrect antiretroviral regimens. Dates were
especially prone to error, and sites had the most difficulty
accurately capturing antiretroviral drug regimens and their
Table 2. Availability of randomly selected clinical records requested by the audit team according to site.
Audit Site Total charts requested
Charts available and
audited
Charts available but not
audited Charts unavailable
A4 0 2 9 01 1
B2 8 2 3 32
C1 7 1 7 00
D2 8 2 7 01
E3 3 2 7 51
F3 5 3 5 00
G2 7 2 6 01
Total 208 184 8 16
doi:10.1371/journal.pone.0033908.t002
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regimens and dates. These findings would trigger strict quality
interventions in prospective clinical trials, which typically require
fewer than 50 errors per 10,000 fields (,0.5% error rate) [20]. In
the context of clinical trials, however, source-to-database audits
like those described here generally report similarly high error rates
when compared to case-report-form-to-database audits [21].
We found that data inconsistencies resulted from how the sites
recorded information in the clinical record, how they abstracted
data for research, and how they entered, stored, and formatted the
data in the electronic database. Many laboratory dates could not
be confirmed because the original laboratory reports had been
discarded, a common practice due to lack of storage space. Errors
in ARV data often resulted from haphazard data abstraction from
paper records used for clinical care. Sites that used rotating
personnel for data abstraction, such as care providers, medical
students, residents, and other trainees, appeared to have higher
rates of ARV data errors compared with those that assembled
focused and well-trained teams. Error rates did not appear to be
associated with the level of experience of the local data
management team or with the presence of a data center. We
currently are performing additional studies to better understand
reasons for data inconsistencies.
The audit functioned as a useful data quality control for both
the data coordinating center and the participating sites. It allowed
the DCC to identify and resolve weaknesses in submitted data
before erroneous data could affect study results and provided sites
with a baseline estimate of their data quality. As a result, all
published CCASAnet studies use revised site data.
The findings prompted us to recommend many of the same
quality improvement interventions for each site:
N Standardize data abstraction, database entry proce-
dures, and personnel training to reduce variability in
data quality. The audit team observed avoidable errors like
improperly selected laboratory dates (laboratory results should
be paired with the date the sample was drawn rather than the
date it was processed or the date of the finalized laboratory
report) and rounded weight values (i.e. 56.7 kg rounded to
56 kg) that led to overall information loss. Such systematic
errors could be prevented by educating data abstractors to
follow consistent rules during data collection and entry.
Table 3. Total number of audited variables and percentage of erroneous data by data type during initial audits at seven sites
a.
Audit Sites
b
AB C D EFG A l l
N %err N %err N %err N %err N %err N %err N %err N %err
Variables
Gender 29 0% 23 0% 17 0% 27 0% 27 0% 35 0% 26 0% 184 0%
Birth date 29 7% 23 9% 17 0% 27 19% 27 0% 35 0% 26 0% 184 5%
Weight 29 31% 37 41% 55 11% 26 38% 27 93% 268 1% 45 2% 487 14%
Weight date 29 21% 37 30% 55 15% 26 38% 27 100% 268 0% 45 9% 487 14%
Laboratory data
CD4 29 14% 33 21% 31 6% 96 13% 132 5% 134 1% 88 5% 543 7%
CD4 date 29 21% 33 27% 31 10% 96 16% 132 17% 134 1% 88 8% 543 12%
Viral load
c 29 7% 26 42% 0 – 57 25% 120 7% 112 1% 84 4% 428 9%
Viral load date
c 29 17% 26 42% 0 – 57 28% 119 13% 112 0% 84 7% 427 12%
Antiretroviral regimen data
Regimen 46 11% 54 26% 23 13% 38 21% 49 22% 67 7% 47 19% 324 17%
Start date 46 28% 54 56% 23 13% 38 32% 49 39% 67 12% 47 26% 324 30%
Stop date 30 27% 54 50% 7 29% 38 29% 49 33% 67 10% 47 38% 292 30%
All 354 17% 400 34% 259 10% 526 21% 758 20% 1299 2% 627 10% 4223 14%
aThis table shows the number of variables audited in each of eleven categories of data, including gender, birth date, weight, CD4 count, viral load, antiretroviral (ARV)
regimens, and all associated dates.
bColumns contain the counts for each site (N), along with the percentage of data that was labeled ‘‘in error’’ by auditors (%err). The reported percentage of erroneous
data includes incorrect, missing, and sourceless values (error categories 3, 4, and 5), but not minor errors.
cSite C did not submit any viral load data.
doi:10.1371/journal.pone.0033908.t003
Figure 1. Error rates by error type for antiretroviral regimens.
The chart shows the rates of overall, incorrect, missing, and sourceless
data errors and their 95% confidence intervals for antiretroviral (ARV)
regimens. The horizontal line represents error rates of 10%.
doi:10.1371/journal.pone.0033908.g001
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or electronic, to encourage consistent provider
documentation and reduce the amount of missing
information. Our audits determined that the majority of
weight-related errors from three sites were due to missing
weight measurements. By replacing the blank sheets of paper
these sites used for clinician notes with a printed form that
prompted providers to record patient weight in a field, some of
these missing values could be prevented.
N Retain laboratory reports whenever possible to
reduce the number of sourceless, unverifiable labo-
ratory values and dates. Sites D, E, and G did not
routinely keep copies of the original laboratory reports in the
patient medical record, resulting in code 5 errors for associated
values (sourceless data). The audit team compared the study
data to handwritten laboratory flowsheets when possible, but
these were not true source documents.
N Revise the procedure for storing dates in the
database so that data abstractors can accurately
record dates that are only known to month or year
precision. We noted that ambiguous dates in the patient
record resulted in frequent date-related errors in ARV
information.
Many of these recommendations are based on standard data
management and clinical trials practices [22]. Each site positively
accepted the feedback and submitted a data quality improvement
plan to the DCC. We have not yet formally studied the impact of
these quality improvement interventions, but early results suggest
that the audit process has led to improved site procedures. Our
first follow-up audit found a 50% decrease in the overall error rate,
with most of the remaining errors resulting from missed data
(values that existed in the clinical chart but were not entered in the
database) rather than incorrect information.
Our study had both strengths and weaknesses. The analysis of
audit findings used a straightforward error categorization system
that required little subjective interpretation, making these findings
easy to replicate. Our multi-lingual auditors were confident
reviewing medical records in French, Spanish, and Portuguese,
and their training allowed them to identify causes of error related
to clinical process and data handling. Potential variation was
minimized by using the same core audit team during every visit.
However, the audit team could inspect only a fraction of records at
each site, so although records were randomly selected for auditing,
the true error rates may differ from the estimated rates reported
here. Furthermore, the audit process evolved as the team gained
experience with each successive audit, so audits performed later
may have been more likely to uncover errors.
Audit results might have been more accurate if auditors had
requested not just a third, but all records on the date of the audit
visit, to discourage sites from reviewing and potentially editing
records in advance. Such an approach, however, might increase
the frequency of selected records being unavailable for audit. We
did not notice any difference in results between records requested
on the date of the audit visit compared to those requested ten days
in advance.
Figure 2. Error rates by error type for start and stop dates of antiretroviral treatment. The two tiled charts show the rates of overall,
incorrect, missing, and sourceless data errors and their 95% confidence intervals for the start and stop dates of patients’ antiretroviral regimens. The
horizontal line represents error rates of 10%.
doi:10.1371/journal.pone.0033908.g002
Table 4. Variable counts and error rates by data category
during initial and follow-up audits at a single site.
Initial
Site Audit Follow-up Site Audit
N %err N %err
Variables
Gender 23 0% 26 0%
Birth date 23 9% 26 8%
Weight 37 41% 42 26%
Weight date 37 30% 42 21%
Laboratory data
CD4 33 21% 35 6%
CD4 date 33 27% 35 6%
Viral load 26 42% 32 16%
Viral load date 26 42% 32 13%
Antiretroviral regimen data
Regimen 54 26% 65 12%
Start date 54 56% 64 23%
Stop date 54 50% 64 33%
All 400 34% 463 17%
doi:10.1371/journal.pone.0033908.t004
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plentiful, and relatively inexpensive medical data for HIV/AIDS
research. Without quality control, however, these data may not be
sufficiently complete or reliable for research. Investigators who
reuse clinical care data must be proactive in addressing potential
quality concerns. To our knowledge, we are the first multi-site
observational HIV cohort that has performed source-to-database
data quality audits. We do not suspect that the error rates observed
in our cohort are substantially higher than those that would be
seen if source-to-database audits were performed in other multi-
center HIV cohorts. Indeed, several of our sites have participated
in other multi-site cohorts such as ART-LINC, TCHARI, and
CHIAC [14,23,24]. We do not claim that the findings of other
multi-center observational HIV cohorts are erroneous, but it is
difficult to interpret study validity without a formal assessment of
data quality. Collaborative research networks – especially those in
international settings – should strongly consider implementing
formal audit programs to evaluate the reliability of their data
sources, to correct discrepancies in data that have already been
collected, and to prevent errors in prospective data collection.
On-location audits require often-scarce resources. In order to
minimize costs, many of our audits were performed during visits
with other scientific objectives. We are currently developing an
electronic audit support tool to help standardize and simplify the
audit process, allowing auditors to import an electronic dataset,
select a set of records to audit, document their findings in real-time
using a pre-defined error taxonomy, and quickly generate
summaries of audit results. We also are exploring the possibility
of incorporating data quality self-assessments as a formal
component of our data quality control procedures. With such an
approach, sites can perform self-assessments of data quality, which
may permit the DCC to reduce the frequency of external audits.
Under certain conditions, audit results can be used to statistically
adjust estimates based on the original, error-containing data [25].
A data audit should be viewed as an important tool for improving
the quality of data, the validity of associated study results, and the
reliability of future data collection procedures.
Supporting Information
Table S1 Example of audit error coding in a compar-
ison of a patient’s antiretroviral drug regimens as
recorded in the database with those found in clinical
records.
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